Decoding 4 Analyst Evaluations For Certara
During the last three months, 4 analysts shared their evaluations of Certara (NASDAQ:CERT), revealing diverse outlooks from bullish…
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies
New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop could impact ETFs.
Certara Introduces Simcyp Biopharmaceutics Software To Increase Efficiency Of Novel And Generic Drug Formulation & Development
Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists
Recap: Certara Q3 Earnings
Certara (NASDAQ:CERT) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:10 PM. Here’s what investors…
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
The Latest Analyst Ratings for Certara
Analysts have provided the following ratings for Certara (NASDAQ:CERT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Certara Announces 300th Regulatory Submission Milestone Using Its Technology-Enabled Services And Software
Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical
Certara Simcyp Group Awarded Two New Grants From U.S. FDA; Amount Not Disclosed
"We are proud to collaborate with the FDA in developing innovative model-informed approaches for accelerating drug development of complex generic and innovator drugs," said Rob Aspbury, President of Certara, Scientific"We are proud to collaborate with the FDA in developing innovative model-informed approaches for accelerating drug development of complex generic and innovator drugs," said Rob As
Benzinga’s Top Ratings Upgrades, Downgrades For August 22, 2023
Upgrades Stifel upgraded the previous rating for Fulcrum Therapeutics Inc (NASDAQ:FULC) from Hold to Buy. For the second…
The Latest Analyst Ratings for Certara
Analysts have provided the following ratings for Certara (NASDAQ:CERT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…